Thermo Fisher Scientific Inc. (NYSE:TMO) Shares Sold by Cedar Brook Financial Partners LLC

Cedar Brook Financial Partners LLC cut its stake in Thermo Fisher Scientific Inc. (NYSE:TMO) by 3.4% in the second quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 701 shares of the medical research company’s stock after selling 25 shares during the period. Cedar Brook Financial Partners LLC’s holdings in Thermo Fisher Scientific were worth $365,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors also recently bought and sold shares of the stock. Connecticut Wealth Management LLC lifted its stake in Thermo Fisher Scientific by 3.0% during the 1st quarter. Connecticut Wealth Management LLC now owns 614 shares of the medical research company’s stock valued at $354,000 after acquiring an additional 18 shares during the period. Sage Rhino Capital LLC lifted its stake in Thermo Fisher Scientific by 2.6% during the 1st quarter. Sage Rhino Capital LLC now owns 723 shares of the medical research company’s stock valued at $417,000 after acquiring an additional 18 shares during the period. Savant Capital LLC lifted its stake in Thermo Fisher Scientific by 0.5% during the 4th quarter. Savant Capital LLC now owns 3,627 shares of the medical research company’s stock valued at $1,997,000 after acquiring an additional 18 shares during the period. Crumly & Associates Inc. increased its holdings in shares of Thermo Fisher Scientific by 1.5% during the 1st quarter. Crumly & Associates Inc. now owns 1,274 shares of the medical research company’s stock valued at $734,000 after purchasing an additional 19 shares in the last quarter. Finally, 1776 Wealth LLC increased its holdings in shares of Thermo Fisher Scientific by 2.4% during the 4th quarter. 1776 Wealth LLC now owns 799 shares of the medical research company’s stock valued at $440,000 after purchasing an additional 19 shares in the last quarter. 87.06% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several research firms have recently weighed in on TMO. Citigroup began coverage on shares of Thermo Fisher Scientific in a report on Wednesday, September 6th. They set a “buy” rating and a $625.00 target price for the company. Royal Bank of Canada boosted their price target on shares of Thermo Fisher Scientific from $662.00 to $698.00 in a report on Thursday, July 27th. Wells Fargo & Company upped their price objective on shares of Thermo Fisher Scientific from $505.00 to $520.00 and gave the stock an “underweight” rating in a research report on Friday, July 28th. KeyCorp reduced their price objective on shares of Thermo Fisher Scientific from $710.00 to $640.00 in a research report on Thursday, May 25th. Finally, Raymond James upped their price objective on shares of Thermo Fisher Scientific from $595.00 to $630.00 and gave the stock an “outperform” rating in a research report on Friday, July 28th. One investment analyst has rated the stock with a sell rating, two have given a hold rating and eleven have issued a buy rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $631.71.

Insiders Place Their Bets

In other news, CEO Marc N. Casper sold 10,000 shares of the firm’s stock in a transaction that occurred on Thursday, August 3rd. The shares were sold at an average price of $549.00, for a total value of $5,490,000.00. Following the completion of the transaction, the chief executive officer now owns 141,330 shares of the company’s stock, valued at $77,590,170. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. In other news, CEO Marc N. Casper sold 10,000 shares of the firm’s stock in a transaction that occurred on Thursday, August 3rd. The shares were sold at an average price of $549.00, for a total value of $5,490,000.00. Following the completion of the transaction, the chief executive officer now owns 141,330 shares of the company’s stock, valued at $77,590,170. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, CEO Marc N. Casper sold 1,600 shares of the firm’s stock in a transaction that occurred on Tuesday, August 8th. The shares were sold at an average price of $550.60, for a total transaction of $880,960.00. Following the completion of the transaction, the chief executive officer now directly owns 135,330 shares of the company’s stock, valued at approximately $74,512,698. The disclosure for this sale can be found here. Insiders sold a total of 28,700 shares of company stock valued at $15,799,270 over the last 90 days. 0.32% of the stock is owned by company insiders.

Thermo Fisher Scientific Trading Up 1.0 %

Shares of TMO opened at $515.64 on Friday. The company has a current ratio of 1.42, a quick ratio of 1.02 and a debt-to-equity ratio of 0.67. Thermo Fisher Scientific Inc. has a 12-month low of $475.77 and a 12-month high of $609.85. The firm has a 50-day moving average price of $540.37 and a 200 day moving average price of $541.88. The firm has a market capitalization of $199.01 billion, a P/E ratio of 35.25, a P/E/G ratio of 2.41 and a beta of 0.77.

Thermo Fisher Scientific (NYSE:TMO) last announced its quarterly earnings data on Wednesday, July 26th. The medical research company reported $5.15 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $5.43 by ($0.28). Thermo Fisher Scientific had a net margin of 13.14% and a return on equity of 18.59%. The firm had revenue of $10.69 billion during the quarter, compared to analysts’ expectations of $10.99 billion. During the same period in the prior year, the company posted $5.51 EPS. The company’s revenue for the quarter was down 2.6% compared to the same quarter last year. Sell-side analysts forecast that Thermo Fisher Scientific Inc. will post 22.37 EPS for the current year.

Thermo Fisher Scientific Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Friday, October 13th. Shareholders of record on Friday, September 15th will be paid a dividend of $0.35 per share. This represents a $1.40 annualized dividend and a yield of 0.27%. The ex-dividend date is Thursday, September 14th. Thermo Fisher Scientific’s dividend payout ratio (DPR) is presently 9.57%.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the United States and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, clinical next-generation sequencing, bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.